BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
148.45 EUR
-4.2 (-2.75%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 83 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP is valued quite cheap, but it does not seem to be growing. This makes IDP very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
In the past year IDP had a positive cash flow from operations.
IDP had positive earnings in each of the past 5 years.
Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 5.51%, IDP is doing good in the industry, outperforming 79.52% of the companies in the same industry.
With a decent Return On Equity value of 8.84%, IDP is doing good in the industry, outperforming 79.52% of the companies in the same industry.
IDP has a better Return On Invested Capital (9.70%) than 84.34% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is in line with the industry average of 12.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP has a better Profit Margin (15.98%) than 81.93% of its industry peers.
IDP's Profit Margin has declined in the last couple of years.
IDP has a better Operating Margin (28.50%) than 84.34% of its industry peers.
In the last couple of years the Operating Margin of IDP has declined.
Looking at the Gross Margin, with a value of 75.24%, IDP is in the better half of the industry, outperforming 65.06% of the companies in the same industry.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.32 indicates that IDP is not in any danger for bankruptcy at the moment.
IDP's Altman-Z score of 3.32 is fine compared to the rest of the industry. IDP outperforms 74.70% of its industry peers.
The Debt to FCF ratio of IDP is 2.78, which is a good value as it means it would take IDP, 2.78 years of fcf income to pay off all of its debts.
IDP has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. IDP outperforms 81.93% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
The Debt to Equity ratio of IDP (0.35) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.32 |
ROIC/WACC1.18
WACC8.25%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Current ratio of 2.72. This is comparable to the rest of the industry: IDP outperforms 59.04% of its industry peers.
A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.56% on average over the next years.
The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IDP is valuated reasonably with a Price/Earnings ratio of 10.39.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 92.77% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.54, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 11.32, which indicates a very decent valuation of IDP.
IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 95.18% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.39 | ||
| Fwd PE | 11.32 |
4.2 Price Multiples
IDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IDP is cheaper than 90.36% of the companies in the same industry.
IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 92.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.28 | ||
| EV/EBITDA | 7.84 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (12/12/2025, 7:00:00 PM)
148.45
-4.2 (-2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap21.78B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.46 (4.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)3.36%
PT rev (3m)6.14%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)-54.42%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-6.19%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.39 | ||
| Fwd PE | 11.32 | ||
| P/S | 2.53 | ||
| P/FCF | 11.28 | ||
| P/OCF | 10.4 | ||
| P/B | 1.4 | ||
| P/tB | 10.7 | ||
| EV/EBITDA | 7.84 |
EPS(TTM)14.29
EY9.63%
EPS(NY)13.11
Fwd EY8.83%
FCF(TTM)13.17
FCFY8.87%
OCF(TTM)14.28
OCFY9.62%
SpS58.58
BVpS105.95
TBVpS13.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.32 |
F-Score5
WACC8.25%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year4.94%
EBIT Next 3Y-0.22%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.79% in the next year.